case_images: PMC9867951_01
case_images: Recorded Activity on LTEEM - Admission Day 3. EEG shows focal onset in the bilateral temporo-occipital lobes characterized by 1.5 Hz periodic discharges evolving into rhythmic 4 Hz delta activity seen predominantly in the bilateral occipital lobes.
case_images: gr1.jpg
case_images: PMC9867951_01_gr1.jpg
case_images: f0005
case_images: On admission day 3, EEG readings showed seizures with a focal onset in the bilateral temporo-occipital lobes characterized by 1.5 Hz periodic discharges, evolving into rhythmic 4 Hz delta activity seen predominantly in the bilateral occipital lobes (Fig. 1).
case_images: The antiseizure medication administration record following the first 2-5 days of admission. Therapy from day 5 was continued until patient's death on day 24. + = Addition of medication |   = Dose increase | - = Removal of medication |   = Continuation of medication and dose.
case_images: gr2.jpg
case_images: PMC9867951_01_gr2.jpg
case_images: f0010
case_images: Notably, after an additional day on the combination regimen of levetiracetam 2 g IV BID, lacosamide 200 mg IV BID, and clobazam oral 10 mg BID, the patient had no further electrographic seizures on day 5 (Fig. 2).
case_images: Recorded Activity on LTEEM - Admission Day 14. EEG shows a similar 1.5 Hz rhythmicity with a wider complex and an almost triphasic appearance resembling LPDs.
case_images: gr3.jpg
case_images: PMC9867951_01_gr3.jpg
case_images: f0015
case_images: LTEEM was resumed on day 14 to monitor disease progression and antiseizure medication efficacy (Fig. 3).